As of 2026-10-07, the Intrinsic Value of TCR2 Therapeutics Inc (TCRR) is -20.77 USD. This TCRR valuation is based on the model Peter Lynch Fair Value. With the current market price of 1.48 USD, the upside of TCR2 Therapeutics Inc is -1,503.43%.
Based on its market price of 1.48 USD and our intrinsic valuation, TCR2 Therapeutics Inc (TCRR) is overvalued by 1,503.43%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -20.77 - -20.77 | -20.77 | -1,503.43% |
| P/E | (74.36) - (103.44) | (85.78) | -5896.2% |
| DDM - Stable | (26.82) - (62.08) | (44.45) | -3103.2% |
| DDM - Multi | (21.09) - (38.57) | (27.33) | -1946.6% |
| Market Cap (mil) | 58.11 |
| Beta | 1.05 |
| Outstanding shares (mil) | 39.26 |
| Enterprise Value (mil) | 43.66 |
| Market risk premium | 4.60% |
| Cost of Equity | 12.43% |
| Cost of Debt | 5.00% |
| WACC | 8.71% |